MYC (Ab-373) Antibody

What is the specificity of MYC (Ab-373) Antibody and what epitope does it recognize?

The MYC (Ab-373) Antibody is a rabbit polyclonal antibody designed to detect endogenous levels of total MYC protein. This antibody specifically recognizes an epitope corresponding to amino acids 371-375 (K-R-S-F-F) derived from Human MYC . The antibody has been affinity-purified using the epitope-specific peptide to ensure high specificity . Western blot analysis typically reveals a band of approximately 60 kDa, which corresponds to the expected molecular weight of MYC protein .

The antibody's specific recognition of this conserved region enables it to detect MYC proteins across multiple species including human, mouse, and rat samples . This cross-species reactivity makes it particularly valuable for comparative studies across different model systems.

What applications has MYC (Ab-373) Antibody been validated for, and what are the recommended dilutions?

The MYC (Ab-373) Antibody has been primarily validated for Western blot (WB) applications, with some sources also indicating utility in immunohistochemistry (IHC) . The recommended dilutions for various applications are:

When optimizing the antibody for specific experimental conditions, it is advisable to perform a dilution series to determine the optimal concentration for your particular sample type and detection system . The optimal dilution may vary depending on the detection method (chemiluminescence, fluorescence, etc.) and the abundance of the target protein in your samples.

How should MYC (Ab-373) Antibody be stored and handled to maintain optimal performance?

Proper storage and handling of MYC (Ab-373) Antibody are crucial for maintaining its activity and specificity. According to product specifications, the following conditions are recommended:

The antibody is typically supplied at a concentration of 1.0 mg/mL in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol . For long-term preservation, store the antibody at -20°C . For short-term use (within a few weeks), storage at 4°C is acceptable .

To minimize freeze-thaw cycles that can degrade antibody performance, it's advisable to prepare small working aliquots before freezing. The antibody is stable for at least one year when stored properly at -20°C . When handling the antibody, avoid contamination and always use clean pipette tips.

How does MYC (Ab-373) Antibody perform in detecting post-translational modifications of MYC protein?

The MYC (Ab-373) Antibody is designed to detect total MYC protein, regardless of most post-translational modifications (PTMs). This contrasts with phospho-specific antibodies like Anti-Myc (phospho-Ser373) Antibody, which specifically recognizes MYC when phosphorylated at Serine 373 .

For researchers investigating MYC phosphorylation status, a strategic approach would be to use both the MYC (Ab-373) Antibody and phospho-specific antibodies in parallel experiments:

• Use MYC (Ab-373) Antibody to determine total MYC protein levels

• Use phospho-specific antibodies to detect specific phosphorylated forms

• Calculate the ratio of phosphorylated to total MYC to quantify relative phosphorylation levels

This dual antibody approach allows researchers to normalize phosphorylation signals to total protein levels, providing more accurate quantification of the PTM status under different experimental conditions.

The MYC protein contains multiple phosphorylation sites that regulate its stability and activity, including Thr58 and Ser62. While the MYC (Ab-373) Antibody detects total MYC regardless of these modifications, the epitope region (aa.371-375) is in close proximity to these regulatory sites, which may potentially affect antibody binding under certain conditions.

Can MYC (Ab-373) Antibody distinguish between different MYC family members (c-MYC, N-MYC, L-MYC)?

The MYC (Ab-373) Antibody targets the amino acid sequence 371-375 (K-R-S-F-F) of human c-MYC . The specificity for c-MYC versus other MYC family members (N-MYC and L-MYC) depends on the conservation of this epitope across the family.

For researchers needing to distinguish between MYC family members, the following approaches are recommended:

• Perform validation experiments using control samples with known expression of specific MYC family members

• Use additional antibodies specifically validated for N-MYC or L-MYC in parallel experiments

• Consider complementary molecular techniques such as RT-PCR with isoform-specific primers

It's important to note that in most adult tissues and common cell lines, c-MYC is the predominant form, while N-MYC and L-MYC show more restricted expression patterns (e.g., N-MYC in neural tissues, L-MYC in lung and neural tissues).

What are the critical steps for optimizing Western blot protocols with MYC (Ab-373) Antibody?

Optimizing Western blot protocols for MYC (Ab-373) Antibody involves attention to several critical parameters:

• Sample preparation:

  • Use RIPA buffer supplemented with protease inhibitors and phosphatase inhibitors

  • For nuclear proteins like MYC, ensure efficient nuclear lysis

  • Fresh samples typically yield better results than frozen ones

• Protein loading:

  • Load 20-50 μg of total protein per lane

  • Include positive control lysates (e.g., HeLa cells) known to express MYC

• Gel percentage and transfer conditions:

  • Use 10% SDS-PAGE gels for optimal resolution of the ~60 kDa MYC protein

  • Transfer at 100V for 1 hour or 30V overnight at 4°C to ensure complete transfer

• Blocking conditions:

  • Block with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

  • For phospho-specific detection, BSA is preferred over milk

• Antibody incubation:

  • Primary antibody (MYC Ab-373): Dilute 1:500-1:1,000 in blocking buffer

  • Incubate overnight at 4°C with gentle rocking

  • Secondary antibody: Anti-rabbit HRP at 1:5,000-1:10,000 for 1 hour at room temperature

• Washing steps:

  • Wash 4-5 times with TBST, 5-10 minutes each

  • Thorough washing reduces background signal

• Detection system:

  • Enhanced chemiluminescence (ECL) is suitable for most applications

  • For low abundance detection, consider using more sensitive ECL substrates

By systematically optimizing these parameters, researchers can achieve clear and specific detection of MYC protein at the expected molecular weight of approximately 60 kDa.

How should samples be prepared to ensure optimal detection of MYC protein using this antibody?

Proper sample preparation is crucial for successful detection of MYC protein, particularly given its nuclear localization and relatively short half-life. The following protocol is recommended:

• Cell harvesting:

  • For adherent cells: Wash with cold PBS, scrape in cold PBS, pellet at 1,500 × g

  • For suspension cells: Pellet cells directly at 1,500 × g

  • Work quickly to minimize protein degradation

• Lysis buffer composition:

  • Base buffer: RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS)

  • Protease inhibitors: 1 mM PMSF, 5 μg/ml aprotinin, 5 μg/ml leupeptin, 5 μg/ml pepstatin

  • Phosphatase inhibitors: 1 mM Na₃VO₄, 10 mM NaF, 1 mM β-glycerophosphate

• Lysis procedure:

  • Add ice-cold lysis buffer (100-200 μl per 10⁶ cells)

  • Incubate on ice for 30 minutes with vortexing every 10 minutes

  • For more complete extraction of nuclear proteins, sonicate briefly (3 × 5 seconds)

  • Centrifuge at 14,000 × g for 15 minutes at 4°C

  • Collect supernatant, avoid the pellet and lipid layer

• Protein quantification:

  • Use BCA or Bradford assay to determine protein concentration

  • Adjust all samples to equal concentration (1-2 μg/μl)

• Sample denaturation:

  • Mix with 4× Laemmli buffer (containing 5% β-mercaptoethanol)

  • Heat at 95°C for 5 minutes

  • Cool on ice before loading

This protocol is designed to maximize protein extraction efficiency while preserving MYC protein integrity and post-translational modifications .

What controls should be included when using MYC (Ab-373) Antibody in experimental workflows?

Including appropriate controls is essential for validating experimental results with MYC (Ab-373) Antibody. The following controls should be considered:

A comprehensive control table for MYC antibody validation is provided below:

Implementing these controls systematically will increase confidence in experimental results and facilitate troubleshooting if unexpected results are obtained.

What approaches can resolve weak or absent signals when using MYC (Ab-373) Antibody?

When encountering weak or absent MYC signals, several troubleshooting approaches can help resolve the issue:

• Sample-related solutions:

  • Increase protein loading (up to 80-100 μg per lane)

  • Use nuclear extraction to concentrate MYC protein

  • Treat cells with proteasome inhibitor (MG132, 10 μM for 4-6 hours) to prevent MYC degradation

  • Verify MYC expression in your samples via RT-qPCR

• Antibody optimization:

  • Decrease antibody dilution (try 1:250-1:500)

  • Extend primary antibody incubation (overnight at 4°C)

  • Test fresh antibody aliquot (avoid freeze-thaw cycles)

  • Consider antibody concentration by commercial concentrators

• Detection enhancement:

  • Use high-sensitivity ECL substrates

  • Extend exposure time (up to overnight for very weak signals)

  • Try alternative detection methods (fluorescent secondary antibodies)

  • Use signal enhancers (e.g., Western Blot Enhancer)

• Protocol modifications:

  • Optimize transfer conditions:

    • Use PVDF membrane instead of nitrocellulose

    • Add 0.1% SDS to transfer buffer for better protein elution

    • Decrease transfer voltage but increase time

  • Modify blocking conditions:

    • Try different blocking agents (milk vs. BSA)

    • Reduce blocking time to prevent masking of epitopes

The following sequential troubleshooting strategy is recommended:

Implementing these strategies systematically, one variable at a time, will help identify and resolve the root cause of weak or absent MYC signals .

What are the common causes of non-specific bands when using MYC (Ab-373) Antibody in Western blots?

Non-specific bands are a common challenge when working with polyclonal antibodies like MYC (Ab-373) Antibody. The most frequent causes and solutions include:

• Cross-reactivity with related proteins:

  • Cause: The antibody may recognize epitopes shared between MYC and related proteins

  • Solution: Validate bands using alternative MYC antibodies targeting different epitopes

• Protein degradation products:

  • Cause: MYC protein has a short half-life and can show degradation bands

  • Solution: Use fresh samples, include protease inhibitors, maintain cold chain

• Post-translational modifications:

  • Cause: Different phosphorylation states can alter migration patterns

  • Solution: Use phosphatase treatment of parallel samples to confirm

• Insufficient blocking:

  • Cause: Inadequate blocking leads to non-specific binding

  • Solution: Extend blocking time or increase blocking agent concentration

• Secondary antibody cross-reactivity:

  • Cause: Secondary antibody may recognize endogenous immunoglobulins

  • Solution: Use secondary antibodies pre-adsorbed against the species of your samples

The following table summarizes common non-specific bands observed with MYC antibodies and their likely identities:

For definitive identification of the true MYC band, immunoprecipitation followed by mass spectrometry can provide conclusive evidence.

How can researchers differentiate between true MYC signals and artifacts when using this antibody?

Distinguishing genuine MYC signals from artifacts requires a systematic approach combining experimental validation and controls:

• Band size verification:

  • True MYC protein appears at ~60 kDa

  • Confirm using molecular weight markers

  • Validate using recombinant MYC protein as a standard

• Peptide competition assay:

  • Pre-incubate antibody with excess immunizing peptide (K-R-S-F-F)

  • True MYC bands should disappear or significantly diminish

  • Persistent bands likely represent non-specific binding

• Genetic validation:

  • Compare samples with different MYC expression levels:

    • Wild-type vs. MYC-knockout/knockdown cells

    • Cells with MYC overexpression vs. controls

  • True MYC bands should show corresponding changes in intensity

• Multiple antibody approach:

  • Probe parallel blots with antibodies targeting different MYC epitopes

  • True MYC bands should be detected by multiple antibodies

  • Example panel: MYC (Ab-373), MYC (9E10), MYC (Y69)

• Biological validation:

  • Examine MYC levels under conditions known to affect expression:

    • Serum stimulation (increases MYC)

    • Contact inhibition (decreases MYC)

    • Cell cycle synchronization (peaks in G1/S)

  • True MYC signals should respond predictably to these conditions

Decision matrix for MYC signal validation:

By applying these validation strategies systematically, researchers can confidently identify true MYC signals and distinguish them from experimental artifacts .

How does the performance of MYC (Ab-373) Antibody vary across different cell lines?

The performance of MYC (Ab-373) Antibody can vary considerably across different cell lines due to biological and technical factors:

• Expression level variations:

  • High MYC expression cells:

    • Embryonic cell lines

    • Cancer cell lines (particularly Burkitt's lymphoma)

    • Rapidly proliferating cells

  • Low MYC expression cells:

    • Differentiated cell lines

    • Quiescent cells

    • Contact-inhibited cells

    • Serum-starved cells

• Cell line-specific detection challenges:

• Validated cell lines:

  • The MYC (Ab-373) Antibody has been validated in:

    • JK cells (human B lymphocytes)

    • HL-60 cells (human promyelocytic leukemia)

    • HUVEC cells (human umbilical vein endothelial)

    • HeLa cells (human cervical adenocarcinoma)

  • These cell lines show reliable detection of the expected ~60 kDa MYC band

• Recommendations for new cell lines:

  • Begin with positive control cells with known MYC expression

  • Optimize protein extraction protocol for the specific cell type

  • For cell lines, synchronize cells to S phase for maximal MYC expression

  • Use phosphatase and protease inhibitors tailored to cell type

By considering these cell line-specific factors, researchers can optimize the performance of MYC (Ab-373) Antibody across diverse experimental systems .

How does MYC (Ab-373) Antibody compare to phospho-specific MYC antibodies in cancer research applications?

MYC (Ab-373) Antibody and phospho-specific MYC antibodies serve complementary roles in cancer research, each providing distinct insights into MYC biology:

• Detection scope:

  • MYC (Ab-373) Antibody: Detects total MYC protein regardless of phosphorylation status

  • Phospho-specific antibodies (e.g., phospho-Ser373): Detect only the phosphorylated subpopulation

• Research applications:

• Cancer-specific considerations:

  • MYC (Ab-373) Antibody is valuable for:

    • Initial screening of MYC expression across tumor samples

    • Normalizing phospho-signals to total protein

    • Comparing absolute MYC levels between tumor and normal tissues

  • Phospho-specific antibodies (e.g., phospho-Ser373) are valuable for:

    • Assessing activation of specific signaling pathways

    • Monitoring drug responses targeting MYC-regulating kinases

    • Studying resistance mechanisms involving altered phosphorylation

• Combined approach benefits:

  • Using both antibody types enables calculation of phosphorylation/total ratios

  • This ratio often correlates better with disease progression than either measure alone

  • Example approach for lymphoma research:

    • MYC (Ab-373) quantifies total MYC (typically elevated)

    • Phospho-specific antibodies indicate pathway activation

For comprehensive cancer research, incorporating both MYC (Ab-373) Antibody and relevant phospho-specific antibodies provides the most complete picture of MYC biology in the tumor microenvironment.

What advantages does MYC (Ab-373) Antibody offer compared to monoclonal MYC antibodies?

MYC (Ab-373) Antibody, being a polyclonal antibody, offers distinct advantages compared to monoclonal antibodies in certain research contexts, while monoclonals may be preferred in others:

• Epitope recognition:

  • MYC (Ab-373) Antibody (Polyclonal): Recognizes epitopes within and around aa.371-375 region

  • Monoclonal antibodies (e.g., 9E10): Recognize single, defined epitope

• Comparative performance analysis:

• Application-specific advantages:

  • MYC (Ab-373) Polyclonal advantages:

    • Superior for detecting low abundance MYC in certain tissues

    • Better tolerance of fixation-induced epitope alterations

    • Often performs better with denatured proteins in Western blots

    • May detect MYC across a broader range of species

  • Monoclonal advantages:

    • Ideal for highly standardized assays requiring reproducibility

    • Superior for quantitative comparisons between experiments

    • Better for distinguishing closely related proteins

    • Preferred for clinical diagnostic applications

• Research scenario recommendations:

  • Choose MYC (Ab-373) Polyclonal when:

    • Detecting MYC in fixed or preserved specimens

    • Working with challenging sample types with low signal

    • Comparing MYC across different species

    • Confirming results from monoclonal antibodies

  • Choose Monoclonal when:

    • Developing standardized assays

    • Performing large-scale screening

    • Conducting longitudinal studies requiring consistent reagents

    • Distinguishing between closely related MYC family members

Understanding these comparative advantages allows researchers to select the most appropriate antibody type for their specific experimental needs.